Pyrotinib or Lapatinib Combined with Capecitabine in Women with HER2-Positive Metastatic Breast Cancer Previously Treated with Taxanes, Anthracyclines, And/Or Trastuzumab: An Open-Label, Randomised, Phase 2 Study

2018 ◽  
Author(s):  
Fei Ma ◽  
Quchang Ouyang ◽  
Binghe Xu ◽  
Wei Li ◽  
Zefei Jiang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Phase 2 ◽  
Her2 Positive ◽  
Open Label ◽  
Phase 2 Study ◽  
Previously Treated

A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS1102-TPS1102 ◽  
Author(s):  
Jose Baselga ◽  
Kenji Tamura ◽  
Toshinari Yamashita ◽  
Shanu Modi ◽  
Eriko Tokunaga ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Phase 2 ◽  
Her2 Positive ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Previously Treated

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

2014 ◽  
Vol 10 (4) ◽  
pp. 368-375 ◽  
Author(s):  
Arlene Chan ◽  
Catherine Shannon ◽  
Richard de Boer ◽  
Sally Baron-Hay ◽  
Andrew Redfern ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Metastatic Breast ◽  
Her2 Positive ◽  
Open Label ◽  
Previously Treated ◽  
Open Label Trial
Sign in / Sign up

Export Citation Format

Share Document